419 related articles for article (PubMed ID: 33704530)
1. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.
Brune MM; Stüssi G; Lundberg P; Vela V; Heim D; Manz MG; Haralambieva E; Pabst T; Banz Y; Bargetzi M; Grobholz R; Fehr M; Cogliatti S; Ossenkoppele GJ; Löwenberg B; Rudolf CB; Li Q; Passweg J; Mazzuchelli L; Medinger M; Tzankov A;
Ann Hematol; 2021 May; 100(5):1169-1179. PubMed ID: 33704530
[TBL] [Abstract][Full Text] [Related]
2. [Angiogenesis in patients with hematologic malignancies].
Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.
Merz LE; Perissinotti AJ; Marini BL; Burke PW; Crouch A; Erba HP; Bixby D
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):24-30. PubMed ID: 31711889
[TBL] [Abstract][Full Text] [Related]
4. Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis.
Lin B; Zhao K; Yang D; Bai D; Liao Y; Zhou Y; Yu Z; Yu X; Guo Q; Lu N
J Cell Physiol; 2019 Feb; 234(2):1913-1924. PubMed ID: 30105796
[TBL] [Abstract][Full Text] [Related]
5. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.
Padró T; Ruiz S; Bieker R; Bürger H; Steins M; Kienast J; Büchner T; Berdel WE; Mesters RM
Blood; 2000 Apr; 95(8):2637-44. PubMed ID: 10753845
[TBL] [Abstract][Full Text] [Related]
6. Study of prognostic significance of marrow angiogenesis assessment in patients with de novo acute leukemia.
AbdElAal Asmaa A; Afify RA; Zaher AE; ElGammal MM; Atef AM
Hematology; 2015 Oct; 20(9):504-10. PubMed ID: 25885121
[TBL] [Abstract][Full Text] [Related]
7. The bone marrow microenvironment - Home of the leukemic blasts.
Shafat MS; Gnaneswaran B; Bowles KM; Rushworth SA
Blood Rev; 2017 Sep; 31(5):277-286. PubMed ID: 28318761
[TBL] [Abstract][Full Text] [Related]
8. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia in the vascular niche.
Cogle CR; Bosse RC; Brewer T; Migdady Y; Shirzad R; Kampen KR; Saki N
Cancer Lett; 2016 Oct; 380(2):552-560. PubMed ID: 25963886
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
Dick FR; Burns CP; Weiner GJ; Heckman KD
Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).
Arber DA; Erba HP
Am J Clin Pathol; 2020 Nov; 154(6):731-741. PubMed ID: 32864703
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).
Kessler T; Koschmieder S; Schliemann C; Crysandt M; Mikesch JH; von Stillfried S; Stelljes M; Pohlen M; Lenz G; Kirsch A; Vehring K; Wardelmann E; Hartmann W; Bormann E; Gerss J; Brümmendorf TH; Müller-Tidow C; Berdel WE
Ann Hematol; 2019 Jun; 98(6):1393-1401. PubMed ID: 30903275
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.
Abou Dalle I; Kantarjian HM; Ravandi F; Daver N; Wang X; Jabbour E; Estrov Z; DiNardo CD; Pemmaraju N; Ferrajoli A; Jain N; Wang SA; Jammal N; Borthakur G; Naqvi K; Pelletier S; Pierce S; Andreeff M; Garcia-Manero G; Cortes JE; Kadia TM
Cancer; 2021 Jun; 127(11):1894-1900. PubMed ID: 33449377
[TBL] [Abstract][Full Text] [Related]
15. De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.
Lopes MR; Pereira JK; de Melo Campos P; Machado-Neto JA; Traina F; Saad ST; Favaro P
Sci Rep; 2017 Jan; 7():40707. PubMed ID: 28084439
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival.
Kuzu I; Beksac M; Arat M; Celebi H; Elhan AH; Erekul S
Leuk Lymphoma; 2004 Jun; 45(6):1185-90. PubMed ID: 15359999
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Fiedler W; Mesters R; Tinnefeld H; Loges S; Staib P; Duhrsen U; Flasshove M; Ottmann OG; Jung W; Cavalli F; Kuse R; Thomalla J; Serve H; O'Farrell AM; Jacobs M; Brega NM; Scigalla P; Hossfeld DK; Berdel WE
Blood; 2003 Oct; 102(8):2763-7. PubMed ID: 12843001
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
19. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
Wang A; Zhong H
Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
[TBL] [Abstract][Full Text] [Related]
20. A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.
Guinn BA; Schuler PJ; Schrezenmeier H; Hofmann S; Weiss J; Bulach C; Götz M; Greiner J
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
